Compare EUDA & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | PDSB |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | 10 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 42.4M |
| IPO Year | 2021 | 2015 |
| Metric | EUDA | PDSB |
|---|---|---|
| Price | $14.80 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.9K | ★ 10.4M |
| Earning Date | 12-19-2023 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $299.28 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.20 |
| 52 Week High | $25.70 | $1.79 |
| Indicator | EUDA | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 59.49 |
| Support Level | $14.21 | $0.60 |
| Resistance Level | $15.36 | $1.40 |
| Average True Range (ATR) | 1.49 | 0.22 |
| MACD | -0.32 | -0.03 |
| Stochastic Oscillator | 28.95 | 47.19 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.